Uscom (ASX:UCM) - Executive Chairman & CEO, Rob Phillips
Executive Chairman & CEO, Rob Phillips
Sourced: Uscom
The Market Herald - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Meditech company Uscom (UCM) has revealed its first quarter of profits in its latest quarterly report
  • Over the March 2020 quarter, Uscom made $740,000 profit
  • Moreover, the newly-formed Uscom China branch made a profit in its first quarter of operations
  • The company claims while the coronavirus has thrust its ultrasound device into the spotlight, the tech has applications far beyond COVID-19
  • Still, Uscom revealed its maiden profit in a market update in late March
  • With no fresh news in today’s report, Uscom shares are trading almost eight per cent lower for 24 cents each

Ultrasound specialist Uscom (UCM) shares are declining today despite the company’s first profitable quarterly report.

Over the March quarter of 2020, Uscom posted a $740,000 profit — a raw difference of $960,000 on the previous corresponding period, given the March 2019 quarter’s $220,000 loss.

Total cash receipts were more than double the same time last year, ending the quarter at $2 million. On the back of this, the company ended the quarter with $2.41 million cash on hand at the end of March compared to the $1.48 million at the end of December.

The solid results are underpinned by a profit in the recently-established Chinese arm of Uscom, which has only been operating for one quarter.

Of course, if the company reported some strong financials over the past quarter, why the share price drop?

No new news

Uscom shares skyrocketed in February when its USCOM 1A ultrasound doppler device started garnering some COVID-19 attention.

The device was recommended — albeit indirectly — by the Hubei government in China to assist the treatment of children who have contracted COVID-19 in mid-February.

Two weeks later, the ultrasound device made the Society of Critical Care Medicine (SCCM) guidelines for treating severe sepsis in children.

Thus, towards the end of March, Uscom tried to capitalise on its time in the spotlight and released a market update in which it revealed the record cash receipts and maiden profits for Uscom China.

Uscom shares spiked the day of the announcement, but one of the side-effects of the early results is today’s lacklustre response to the official 4C quarterly report.

Shareholders may have been hoping for fresh news with today’s report, prompting the dip in shares.

COVID-19: Just the beginning?

However, the company was confident the coming quarters will bring more business Uscom’s way as more countries respond to coronavirus concerns.

Uscom said while China’s response to COVID-19 was rapid and decisive, other countries have been slower. As such, the company is expecting an uptake in USCOM 1A sales, particularly in the U.S. and Europe, as more governments recognise the benefits of the tech.

“Uscom sees the COVID-19 pandemic as supplementing an already strong growth business model based on advances haemodynamic care in infections, heart failure, pregnancy, hypertension, post-operative care, anaesthesia and fluid management in adults and children,” the company said.

Executive Chairman Professor Rob Phillips made it clear the company has plans beyond COVID-19:

“Uscom is more than a simple COVID-19 company; we are leaders in non-invasive cardiovascular and pulmonary medical devices with multiple life-saving technologies — COVID-19 is just one of our many critical clinical applications,” Rob explained.

Still, shareholders will have to play the waiting game to see these other applications spring to life.

Shares in Uscom have dipped 7.69 per cent by mid-afternoon trade, currently worth 24 cents each.

UCM by the numbers
More From The Market Herald

The Calmer Co locks in $700k in funding via convertible note issue

The Calmer Co (ASX:CCO) has confirmed its receipt of $700,000 in funding from existing shareholders.

FDA greenlights Botanix Pharmaceuticals’ Sofdra resubmission plan

FDA approves Botanix's strategy for Sofdra NDA resubmission with no additional materials requested, keeping submission to…

Botanix Pharmaceuticals successfully closes $13.5m Placement to boost US commercial activities

Botanix Pharmaceuticals (ASX: BOT) has closed its $13.5 million placement to both new and existing institutional…

Pharmaust completes Phase One Monepantel study and files for Orphan Drug Designation

Pharmaust (ASX:PAA) has announced that all patients have completed its phase one MEND study using monepantel…